Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Hydroxychloroquine Articles

Combining medications often best strategy to battle rheumatoid arthritis; study

3 December 2007

After 40 years waiting, glimmer of light at the end of the tunnel for SLE patients

2 October 2006

New lupus drug launched in China

17 July 2001

FDA plans review of guidances on development of generic drugs

14 July 1999

New drugs boost Sanofi's 1998 sales

27 January 1999

New drugs boost Sanofi's 1998 sales

25 January 1999

Sanofi Produces Strong First-Half Sales Growth

24 July 1998

Sanofi Pharma Sales Held Back In West Europe, But Up 10%

4 February 1998

More Bad Trial News For AutoImmune

19 May 1997

Strong Sales At Sanofi In 4th Qtr

17 February 1997

Good Sales In 1996 2nd Qtr Says Sanofi

5 August 1996

1996 A Transitional Year For Royce

24 June 1996

Autoimmune's Oral Tolerance Drugs Reach Pivotal Stage

20 May 1996

FDA Panel Rejects Pfizer's Tenidap Application

13 May 1996

1st-Qtr Sales Rise 2% At Sanofi

13 May 1996

Royce Labs: hydroxychloroquine

4 December 1995

Pfizer's Enablex Slows Progression of Arthritis

31 October 1994

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS